GlassScriptPhysician profile
Min Qiao Grant
NPI 1679133698
$1,808.05
in general payments reported to CMS, 2019-2025
22 companies · $1,622 in 2025
The $1,622 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $123 · 2024: $63.69 · 2025: $1,622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,808.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $553.54 | 2025 | Ponvory |
| Argenx US, INC. | $142.71 | 2025 | Vyvgart Hytrulo |
| Harmony Biosciences LLC | $130.69 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $122.68 | 2023 | Zeposia |
| Novartis Pharmaceuticals Corporation | $104.34 | 2025 | |
| Alexion Pharmaceuticals, INC. | $85.12 | 2024-2025 | Ultomiris |
| Lundbeck LLC | $78.92 | 2025 | Vyepti, Rexulti |
| Tg Therapeutics, INC. | $77.00 | 2024-2025 | |
| Octapharma USA, INC. | $59.44 | 2025 | Panzyga |
| Tanabe Pharma America, INC. | $57.28 | 2025 | Radicava |
| Amgen INC. | $51.10 | 2025 | Uplizna |
| Avadel Cns Pharmaceuticals, LLC | $51.04 | 2025 | Lumryz |
| Springworks Therapeutics, INC. | $41.62 | 2025 | Gomekli |
| Neurocrine Biosciences, INC. | $39.68 | 2025 | |
| Axsome Therapeutics, INC. | $38.42 | 2025 | Sunosi, Symbravo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $37.61 | 2025 | Austedo Xr |
| Eisai INC. | $27.63 | 2025 | |
| Cycle Pharmaceuticals INC | $25.77 | 2025 | Tascenso Odt, Bafiertam |
| Abbvie INC. | $25.05 | 2025 | |
| Azurity Pharmaceuticals, INC. | $21.61 | 2025 | Horizant |
| Otsuka America Pharmaceutical, INC. | $20.58 | 2025 | Rexulti |
| Pfizer INC. | $16.22 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Min Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.